These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups. Li X, Liu Y, Zhang YK, Plattner JJ, Baker SJ, Bu W, Liu L, Zhou Y, Ding CZ, Zhang S, Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A. Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7351-6. PubMed ID: 23142614 [Abstract] [Full Text] [Related]
4. Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate. Milanole G, Andriessen F, Lemonnier G, Sebban M, Coadou G, Couve-Bonnaire S, Bonfanti JF, Jubault P, Pannecoucke X. Org Lett; 2015 Jun 19; 17(12):2968-71. PubMed ID: 26053226 [Abstract] [Full Text] [Related]
5. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease. Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J. Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7317-22. PubMed ID: 21067923 [Abstract] [Full Text] [Related]
12. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao SS, McIntyre CJ, Nguyen KT, Romano JJ, Stahlhut M, Wan BL, Olsen DB, Vacca JP. J Am Chem Soc; 2008 Apr 09; 130(14):4607-9. PubMed ID: 18338894 [Abstract] [Full Text] [Related]
13. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V. J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065 [Abstract] [Full Text] [Related]
16. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320. Parsy CC, Alexandre FR, Bidau V, Bonnaterre F, Brandt G, Caillet C, Cappelle S, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos LB, Leroy F, Liuzzi M, Loi AG, Moulat L, Chiara M, Rahali H, Roques V, Rosinovsky E, Savin S, Seifer M, Standring D, Surleraux D. Bioorg Med Chem Lett; 2015 Nov 15; 25(22):5427-36. PubMed ID: 26410074 [Abstract] [Full Text] [Related]
17. Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants. Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A, Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L. J Med Chem; 2012 Apr 12; 55(7):3021-6. PubMed ID: 22471376 [Abstract] [Full Text] [Related]
18. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors. Sheng XC, Pyun HJ, Chaudhary K, Wang J, Doerffler E, Fleury M, McMurtrie D, Chen X, Delaney WE, Kim CU. Bioorg Med Chem Lett; 2009 Jul 01; 19(13):3453-7. PubMed ID: 19477126 [Abstract] [Full Text] [Related]